1. bookVolume 55 (2017): Edition 1 (March 2017)
Détails du magazine
License
Format
Magazine
eISSN
2501-062X
Première parution
30 Mar 2015
Périodicité
4 fois par an
Langues
Anglais
Accès libre

Different effects of anti-TNF-alpha biologic drugs on the small bowel macroscopic inflammation in patients with ankylosing spondylitis

Publié en ligne: 04 Mar 2017
Volume & Edition: Volume 55 (2017) - Edition 1 (March 2017)
Pages: 44 - 52
Reçu: 01 Nov 2016
Détails du magazine
License
Format
Magazine
eISSN
2501-062X
Première parution
30 Mar 2015
Périodicité
4 fois par an
Langues
Anglais

1. CIUREA A., SCHERER A., EXER P., BERNHARD J., DUDLER J., BEYELER B., et al. Tumor necrosis factor alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. 2013; 65(12):3096-106.10.1002/art.38140Search in Google Scholar

2. LEIRISALO-REPO M., TURUNEN U., STENMAN S., HELENIUS P., SEPPALA K. High frequency of silent inflammatory bowel disease in spondylarthropathy. Arthritis Rheum. 1994; 37(1):23-31.10.1002/art.1780370105Search in Google Scholar

3. DE KEYSER F., MIELANTS H. The gut in ankylosing spondylitis and other spondyloarthropathies: inflammation beneath the surface. J Rheumatol. 2003; 30(11):2306-7.Search in Google Scholar

4. DE KEYSER F., ELEWAUT D., DE VOS M., DE VLAM K., CUVELIER C., MIELANTS H., et al. Bowel inflammation and the spondyloarthropathies. Rheum Dis Clin North Am. 1998; 24(4):785-813, ix-x.10.1016/S0889-857X(05)70042-9Search in Google Scholar

5. BRADLEY J.R. TNF-mediated inflammatory disease. The Journal of Pathology. 2008; 214(2):149-60.10.1002/path.2287Search in Google Scholar

6. BRAUN J., SIEPER J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin Biol Ther. 2003; 3(1):141-68.10.1517/14712598.3.1.141Search in Google Scholar

7. VAN DULLEMEN H.M., VAN DEVENTER S.J., HOMMES D.W., BIJL H.A., JANSEN J., TYTGAT G.N., et al. Treatment of Crohn’s disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology. 1995; 109(1):129-35.10.1016/0016-5085(95)90277-5Search in Google Scholar

8. D’HAENS G., VAN DEVENTER S., VAN HOGEZAND R., CHALMERS D., KOTHE C., BAERT F., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology. 1999; 116(5):1029-34.10.1016/S0016-5085(99)70005-3Search in Google Scholar

9. FORD A.C., SANDBORN W.J., KHAN K.J., HANAUER S.B., TALLEY N.J., MOAYYEDI P. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011; 106(4):644-59, quiz 60.Search in Google Scholar

10. JARNEROT G., HERTERVIG E., FRIIS-LIBY I., BLOMQUIST L., KARLEN P., GRANNO C., et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology. 2005; 128(7):1805-11.10.1053/j.gastro.2005.03.00315940615Search in Google Scholar

11. SONG I.H., PODDUBNYY D.A., RUDWALEIT M., SIEPER J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2008; 58(4):929-38.10.1002/art.2327518383378Search in Google Scholar

12. WATANABE T., TANIGAWA T., SHIBA M., NADATANI Y., NAGAMI Y., SUGIMORI S., et al. Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients. Gut. 2014; 63(3):409-14.10.1136/gutjnl-2013-30471323697473Search in Google Scholar

13. MAIDEN L., THJODLEIFSSON B., THEODORS A., GONZALEZ J., BJARNASON I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology. 2005; 128(5):1172-8.10.1053/j.gastro.2005.03.02015887101Search in Google Scholar

14. WATANABE T., TANIGAWA T., NADATANI Y., OTANI K., MACHIDA H., OKAZAKI H., et al. Mitochondrial disorders in NSAIDs-induced small bowel injury. J Clin Biochem Nutr. 2011; 48(2):117-21.10.3164/jcbn.10-73304568321373263Search in Google Scholar

15. BABB R.R. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs. West J Med. 1992; 157(4):444-7.Search in Google Scholar

16. SIGTHORSSON G., TIBBLE J., HAYLLAR J., MENZIES I., MACPHERSON A., MOOTS R., et al. Intestinal permeability and inflammation in patients on NSAIDs. Gut. 1998; 43(4):506-11.10.1136/gut.43.4.50617272929824578Search in Google Scholar

17. APPLEYARD C.B., MCCAFFERTY D.M., TIGLEY A.W., SWAIN M.G., WALLACE J.L. Tumor necrosis factor mediation of NSAID-induced gastric damage: role of leukocyte adherence. Am J Physiol. 1996; 270(1 Pt 1):G42-8.10.1152/ajpgi.1996.270.1.G428772499Search in Google Scholar

18. CICCIA F., RIZZO A., TRIOLO G. Subclinical gut inflammation in ankylosing spondylitis. Curr Opin Rheumatol. 2016; 28(1):89-96.10.1097/BOR.000000000000023926599385Search in Google Scholar

19. GRALNEK I.M., DEFRANCHIS R., SEIDMAN E., LEIGHTON J.A., LEGNANI P., LEWIS B.S. Development of a capsule endoscopy scoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther. 2008; 27(2):146-54.10.1111/j.1365-2036.2007.03556.x17956598Search in Google Scholar

20. ORLANDO A., RENNA S., PERRICONE G., COTTONE M. Gastrointestinal lesions associated with spondyloarthropathies. World J Gastroenterol. 2009; 15(20):2443-8.10.3748/wjg.15.2443268690019468992Search in Google Scholar

21. DE KEYSER F., BAETEN D., VAN DEN BOSCH F., DE VOS M., CUVELIER C., MIELANTS H., et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep. 2002; 4(6):525-32.10.1007/s11926-002-0061-612427369Search in Google Scholar

22. MIELANTS H., DE KEYSER F., BAETEN D., VAN DEN BOSCH F. Gut inflammation in the spondyloarthropathies. Curr Rheumatol Rep. 2005; 7(3):188-94.10.1007/s11926-996-0038-y15918994Search in Google Scholar

23. ELEWAUT D. Linking Crohn’s Disease and Ankylosing Spondylitis: It’s All about Genes! PLoS Genet. 2010; 6(12).10.1371/journal.pgen.1001223299632221152009Search in Google Scholar

24. RUDWALEIT M., BAETEN D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006; 20(3):451-71.10.1016/j.berh.2006.03.010Search in Google Scholar

25. SENABRE-GALLEGO JÉ M., SANTOS-RAMÍREZ C., SANTOS-SOLER G., SALAS-HEREDIA E., SÁNCHEZ-BARRIOLUENGO M., BARBER X., et al. Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis. Patient Prefer Adherence. 2013; 7:961-72.10.2147/PPA.S33109Search in Google Scholar

26. VAN DEVENTER S.J. Transmembrane TNF-alpha, induction of apoptosis, and the efficacy of TNF-targeting therapies in Crohn’s disease. Gastroenterology. 2001; 121(5):1242-6.10.1053/gast.2001.29035Search in Google Scholar

27. GOLAN D.E., TASHJIAN A.H. Principles of pharmacology : the pathophysiologic basis of drug therapy. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2012.Search in Google Scholar

28. VAN DEN BRANDE J.M.H., BRAAT H., VAN DEN BRINK G.R., VERSTEEG H.H., BAUER C.A., HOEDEMAEKER I., et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease. Gastroenterology. 2003; 124(7):1774-85.10.1016/S0016-5085(03)00382-2Search in Google Scholar

29. MARZO-ORTEGA H., MCGONAGLE D., O’CONNOR P., EMERY P. Efficacy of etanercept for treatment of Crohn’s related spondyloarthritis but not colitis. Ann Rheum Dis. 2003; 62(1):74-6.10.1136/ard.62.1.74175430612480676Search in Google Scholar

30. KRUITHOF E., DE RYCKE L., ROTH J., MIELANTS H., VAN DEN BOSCH F., DE KEYSER F., et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum. 2005; 52(12):3898-909.10.1002/art.2142616329106Search in Google Scholar

31. VAN DER HEIJDE D., DIJKMANS B., GEUSENS P., SIEPER J., DEWOODY K., WILLIAMSON P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005; 52(2):582-91.10.1002/art.2085215692973Search in Google Scholar

32. KRUITHOF E., BAETEN D., VAN DEN BOSCH F., MIELANTS H., VEYS E.M., DE KEYSER F. Histological evidence that infliximab treatment leads to downregulation of inflammation and tissue remodelling of the synovial membrane in spondyloarthropathy. Ann Rheum Dis. 2005; 64(4):529-36.10.1136/ard.2003.018549175546115388510Search in Google Scholar

33. BRAUN J., BARALIAKOS X., LISTING J., DAVIS J., VAN DER HEIJDE D., HAIBEL H., et al. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 2007; 57(4):639-47.10.1002/art.2266917471540Search in Google Scholar

34. PODDUBNYY D. Axial spondyloarthritis: is there a treatment of choice? Ther Adv Musculoskelet Dis. 2013; 5(1):45-54.10.1177/1759720X12468658358230523514983Search in Google Scholar

35. MIELANTS H., VEYS E.M., DE VOS M., CUVELIER C., GOEMAERE S., DE CLERCQ L., et al. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects. J Rheumatol. 1995; 22(12):2266-72.Search in Google Scholar

36. MIELANTS H., VEYS E.M., CUVELIER C., DE VOS M., GOEMAERE S., DE CLERCQ L., et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol. 1995; 22(12):2279-84.Search in Google Scholar

37. MIELANTS H., VEYS E.M., CUVELIER C., DE VOS M., GOEMAERE S., DE CLERCQ L., et al. The evolution of spondyloarthropathies in relation to gut histology. II. Histological aspects. J Rheumatol. 1995; 22(12):2273-8.Search in Google Scholar

Articles recommandés par Trend MD

Planifiez votre conférence à distance avec Sciendo